Miltefosine, an FDA-approved drug for the ‘orphan disease’, leishmaniasis

Bibliography

• FDA. Developing Products for Rare Diseases & Conditions. Available from: http://www.fda.gov/orphan/designat/index.htm [Accessed 24 February 2015]
   Google Scholar
• FDA. Tropical Disease Priority Review Voucher. 2008. Available from: http://www.fda.gov/downloads/Drugs/Guidances/UCM080599.pdf [Accessed 24 February 2015]
   Google Scholar
• Wall Street Journal. How Much? Gilead Pays $125M For an FDA. Priority Review Voucher. 19 November 2014
   Google Scholar
• WHO. Control of the leishmaniases. WHO Technical report series # 949. 2010.
   Google Scholar
• Sindermann H, Engel KR, Fischer C, et al. Oral Miltefosine for Leishmaniasis in immunocompromized patients. Compassionate use in 39 patients with HIV infection. Clin Infect Dis 2004;39:1520-3
   PubMed Web of Science ®Google Scholar
• Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg 1992;46:296-306
   PubMed Web of Science ®Google Scholar
• Berman J. Effects of ketoconazole on sterol biosynthesis by Leishmania mexicana mexicana amastigotes in murine macrophage tumor cells. Mol Biochem Parasitol 1986;20:85-92
   PubMed Web of Science ®Google Scholar
• FDA. Ambisome label. 2000. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/50740S001_AmBisome_prntlbl.pdf
   Google Scholar
• Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet 2005;366:1561-77
   PubMed Web of Science ®Google Scholar
• Gonzalez U, Pinart M, Reveiz L, et al. Designing and reporting clinical trials on treatments for cutaneous leishmaniasis. Clin Infect Dis 2010;51:409-19
   PubMed Web of Science ®Google Scholar
• Sindermann H, Engel J. Development of miltefosine as an oral treatmentfor leishmaniasis. Trans R Soc Trop Med Hyg 2006;100(Suppl 1):S17-20
   PubMedGoogle Scholar
• FDA. Miltefosine Label. 2014. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204684s000lbl.pdf [Accessed 24 February 2015]
   Google Scholar
• Sundar S, Rosenkaimer F, Makharia MK, et al. Trial of oral miltefosine for visceral leishmaniasis. Lancet 1998;352:1821-3
   PubMed Web of Science ®Google Scholar
• Jha TK, Sundar S, Thakur CP, et al. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med 1999;341:1795-800
   PubMed Web of Science ®Google Scholar
• Sundar S, Makharia A, More DK, et al. Short-course of oral miltefosine for treatment of visceral leishmaniasis. Clin Infect Dis 2000;31:1110-13
   PubMed Web of Science ®Google Scholar
• Sundar S, Jha TK, Thakur CP, et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002;347:1739-46
   PubMed Web of Science ®Google Scholar
• Bhattacharya SK, Jha TK, Sundar S, et al. Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India. Clin Infect Dis 2004;38:217-21
   PubMed Web of Science ®Google Scholar
• Sundar S, Singh A, Rai M, et al. Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. Clin Infect Dis 2012;55:543-50
   PubMed Web of Science ®Google Scholar
• Ritmeijer K, Dejenie A, Assefa Y, et al. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clin Infect Dis 2006;43:357-64
   PubMed Web of Science ®Google Scholar
• Soto J, Arana BA, Toledo J, et al. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 2004;38:1266-72
   PubMed Web of Science ®Google Scholar
• Chrusciak-Talhari A, Dietze R, Chrusciak Talhari C, et al. Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil. Am J Trop Med Hyg 2011;84:255-60
   PubMed Web of Science ®Google Scholar
• Machado PR, Ampuero J, Guimarães LH, et al. Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial. PLoS Negl Trop Dis 2010;4(12):e912
   PubMed Web of Science ®Google Scholar
• Soto J, Toledo J, Valda L, et al. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis 2007;44:350-6
   PubMed Web of Science ®Google Scholar
• Zerpa O, Ulrich M, Blanco B, et al. Diffuse cutaneous leishmaniasis responds to miltefosine but then relapses. Br J Dermatol 2007;156:1328-35
   PubMed Web of Science ®Google Scholar
• Sundar S, Kumar K, Chakravarty J, et al. Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine. Trans R Soc Trop Med Hyg 2006;100:698-700
   PubMed Web of Science ®Google Scholar
• Vélez I, López L, Sánchez X, et al. Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis. Am J Trop Med Hyg 2010;83:351-6
   PubMed Web of Science ®Google Scholar
• Rubiano LC, Miranda MC, Muvdi Arenas S, et al. Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children. J Infect Dis 2012;205:684-92
   PubMed Web of Science ®Google Scholar
• Saenz RE, Paz H, Berman JD. Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis. Am J Med 1990;89:147-55
   PubMed Web of Science ®Google Scholar
• Sundar S, Chakravarty J, Agarwal D, et al. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 2010;362:504-12
   PubMed Web of Science ®Google Scholar
• Sundar S, Sinha PK, Rai M, et al. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet 2011;377:477-86
   PubMed Web of Science ®Google Scholar
• Sundar S, Jha TK, Thakur CP, et al. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin Infect Dis 2003;37:800-4
   PubMed Web of Science ®Google Scholar
• Khalil EA, Weldegebreal T, Younis BM, et al. Safety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: a randomised trial. PLoS Negl Trop Dis 2014;8(1):e2613
   PubMed Web of Science ®Google Scholar
• FDA Briefing Document for the Anti-Infective Drugs Advisory Committee Meeting October 18, 2013 [Miltefosine]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM371074.pdf [Accessed 11 March 2015]
   Google Scholar
• Paladin Presentations for the October 18, 2013 [Miltefosine] Meeting of the Anti-Infective Drugs Advisory Committee. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM383475.pdf [Accessed 11 March 2015]
   Google Scholar